$PRLD

Prelude Therapeutics Inc (PRLD): Submission of Matters to a Vote of Security Holders

Prelude Therapeutics Inc (PRLD) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001678660 false 0001678660 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2

Original reporting
Published Jun 10, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$PRLD
Neutral
high confidence
Mentioned
$PRLD
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PRLDNeutralLow
01

Why it matters

The disclosed items are director elections, ratification of Ernst & Young LLP as auditor for FY ending Dec. 31, 2026, and advisory votes on 2025 executive compensation and the frequency of future advisory votes (1 year).

02

Market read

This is a routine governance disclosure with no new operating or financial guidance, clinical data, or regulatory action.

03

What to watch

Traders should focus on upcoming substantive catalysts (clinical updates, financing, regulatory milestones) rather than advisory vote results.

Relevance 6/10Novelty 2/10Timing: after-hours/filing date (June 10, 2026) following June 9 annual meeting

Background

The filing is an SEC 8-K Item 5.07 summarizing matters submitted to a vote of security holders at Prelude Therapeutics’ 2026 annual meeting on June 9, 2026.

Company-level read

Ticker impact

$PRLDNeutralHigh confidence
Context

Prelude Therapeutics reported stockholder voting results for its 2026 annual meeting, including director elections and advisory compensation votes.

Expected impact

Low likelihood of a sustained price move; any reaction would be limited to sentiment around governance/compensation.

Evidence & confidence

The 8-K discloses voting tallies and ratification of auditors and advisory votes, with no new clinical, financial, regulatory, or deal catalyst.

Market effects

Minimal; governance vote outcomes do not typically reset biotech risk or read-across expectations.

None indicated.

None indicated.

Counterpoint

If investors were concerned about governance/compensation alignment, the approval could reduce overhang, but the filing provides no evidence of a contested issue.

Key entities

  • Prelude Therapeutics Incorporated

    Company filing the 8-K and reporting annual meeting voting results.

  • Ernst & Young LLP

    Ratified as independent registered public accounting firm for fiscal year ending December 31, 2026.

  • Krishna Vaddi

    Elected Class III director for a three-year term.

  • Paul Scherer

    Elected Class III director for a three-year term.

  • Katina Dorton

    Elected Class III director for a three-year term.

Related articles

$PRLDMed

Prelude Therapeutics Inc (PRLD): Results of Operations and Financial Condition

Prelude Therapeutics Inc (PRLD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter Presented

$TRIBMed

Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?

Biotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.

$AONHighAI 9/10

Aon raises $13.75 billion to support USI acquisition

Aon raised $13.75 billion in senior notes, guaranteed by its subsidiaries, with maturities from 2029 to 2056 and coupons ranging from 5.350% to 6.450%. The funds, approximately $13.4 billion after expenses, will support the USI Advantage Corp. acquisition and general corporate purposes. The notes include redemption protections tied to the deal's completion.